Mineralys Therapeutics Inc. has announced the suspension and termination of its prospectus supplement related to the sale of its common stock under the ATM Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. The prospectus, initially filed on April 11, 2024, will no longer facilitate stock sales until a new supplement is filed with the Securities and Exchange Commission. Despite this suspension, the Sales Agreement itself remains active. The original Sales Agreement was part of the company's Registration Statement submitted on March 21, 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001933414-25-000107), on September 02, 2025, and is solely responsible for the information contained therein.